AbbVie's RINVOQ® (upadacitinib) Met Primary and All Ranked Secondary Endpoints in Phase 3 Study in Ankylosing Spondylitis
/PRNewswire/ -- AbbVie (NYSE: ABBV) today announced positive top-line results from the first of two studies of the Phase 3 SELECT-AXIS 2 clinical trial...
Michael Severino European Commission Drug Administration Exchange Commission Spondyloarthritis Research Consortium Of Canada Assessment In Spondyloarthritis International Society
Source: prnewswire.com